Overview
Ustekinumab is a biologic that targets interleukins IL-12 and IL-23 — key cytokines in the inflammatory cascade of Crohn's disease and ulcerative colitis. It is given as a single intravenous dose for induction, then as subcutaneous injections for maintenance every 8 or 12 weeks.
Key Uses
Moderate-to-severe Crohn's disease (including after anti-TNF failure)
Moderate-to-severe ulcerative colitis
Also approved for plaque psoriasis and psoriatic arthritis
How It Works
Binds the p40 subunit shared by IL-12 and IL-23, blocking their pro-inflammatory signalling
Reduces Th1 and Th17 immune cell activity — key drivers of IBD inflammation
Induction: single weight-based IV infusion; maintenance: 90 mg SC every 8 or 12 weeks
Favourable safety profile — one of the lowest infection rates among IBD biologics
Safety & Self-Care
TB and hepatitis B screening before starting
Generally well tolerated — injection site reactions and mild upper respiratory infections are most common side effects
Avoid live vaccines; keep inactivated vaccines current
Self-injection can be learned at the clinic — training is provided
Store pre-filled syringes in the refrigerator; allow to reach room temperature before injecting
Contact Your IMCC Team
Contact your IMCC team if symptoms flare between doses, you develop infection signs, or if you are planning pregnancy or any surgical procedure.
Share this with someone who needs it: